Patents Assigned to Santen Pharmaceutical Co.,
  • LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
    Publication number: 20180311152
    Abstract: Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.
    Type: Application
    Filed: November 7, 2017
    Publication date: November 1, 2018
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Sreenivasu MUDUMBA, Philippe JM DOR, Thierry NIVAGGIOLI, David A. WEBER, Sidiq FAROOQ
  • METHOD AND COMPOSITION FOR TREATING OCULAR HYPERTENSION AND GLAUCOMA
    Publication number: 20180289618
    Abstract: The present invention relates to an ophthalmic aqueous composition containing PGF2? analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2? analogues in an aqueous composition.
    Type: Application
    Filed: June 18, 2018
    Publication date: October 11, 2018
    Applicants: Santen Pharmaceutical Co., Ltd., Asahi Glass Co., LTD.
    Inventors: Timo REUNAMAKI, Pertti PELLINEN, Olli OKSALA, Kari LEHMUSSAARI
  • FUNGAL KERATITIS PROPHYLACTIC OR THERAPEUTIC AGENT
    Publication number: 20180271841
    Abstract: For preventing or treating keratomycosis, a medicament containing rapamycin or a salt thereof as an active ingredient is used.
    Type: Application
    Filed: September 13, 2016
    Publication date: September 27, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Jinzhong ZHANG, Masaaki KAGEYAMA
  • Ophthalmic solution comprising diquafosol
    Patent number: 10071113
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: September 11, 2018
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF
    Publication number: 20180244633
    Abstract: The present invention relates to a novel [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or a salt thereof. The compound or a salt thereof of the present invention has a glucocorticoid receptor agonist activity, and is useful as a medicine, in particular as a prophylactic or therapeutic agent for the glucocorticoid receptor related disease.
    Type: Application
    Filed: August 25, 2016
    Publication date: August 30, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji KAWASHIMA, Yusuke YAMAZAKI, Shinji TAKAOKA, Daisuke SHII, Tomoko ODA, Takahiro MATSUYAMA
  • METHOD FOR CHANGING CONDITION OF EYELID OF HAIRLESS ANIMAL
    Publication number: 20180246081
    Abstract: A method for changing a condition of an eyelid of a hairless animal, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki MIYAKE, Tomoko ODA
  • PROPHYLACTIC AND/OR THERAPEUTIC AGENT CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND
    Publication number: 20180200239
    Abstract: The object of the present invention is to find a new application of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof. Isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof is useful as a therapeutic agent for a disease involving a greatly elevated intraocular pressure.
    Type: Application
    Filed: July 7, 2016
    Publication date: July 19, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Tomoko KIRIHARA, Atsushi SHIMAZAKI, Najam A. SHARIF
  • PHARMACEUTICAL FORMULATIONS COMPRISING A PYRIDYLAMINOACETIC ACID COMPOUND
    Publication number: 20180169079
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 21, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed SHAMS, Henk-Andre KROON, Hisashi KAWATA, Noriko KAWABATA
  • Method and composition for treating ocular hypertension and glaucoma
    Patent number: 9999593
    Abstract: The present invention relates to an ophthalmic aqueous composition containing PGF2? analogs for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2? analogs in an aqueous composition.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: June 19, 2018
    Assignees: SANTEN PHARMACEUTICAL CO., LTD., ASAHI GLASS CO., LTD.
    Inventors: Timo Reunamaki, Pertti Pellinen, Olli Oksala, Kari Lehmussaari
  • Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland blockage
    Patent number: 9999594
    Abstract: The objective of the present invention is to provide a new medicinal use of clarithromycin. The present invention is a therapeutic agent or a preventive agent for meibomian gland dysfunction or meibomian gland blockage and comprises clarithromycin as an active ingredient. The dosage form is preferably an eye drop or eye ointment.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: June 19, 2018
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kazutaka Kido, Takashi Nagano
  • Pharmaceutical composition comprising polypeptide
    Patent number: 9987368
    Abstract: Found out is a pharmaceutical composition that sustained-releases a drug for a long term after administration into the body. Provided is a pharmaceutical composition comprising a drug and a polypeptide represented by Ac-(Arg-Ala-Asp-Ala)4-NH2, and further containing an organic solvent selected from the group consisting of polyethylene glycol, dimethyl sulfoxide, glycofurol, and N-methylpyrrolidone.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: June 5, 2018
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Tatsuya Miyazaki, Kenji Masaki, Komei Okabe, Kazuhito Yamada
  • Intraocular lens injector
    Patent number: 9987128
    Abstract: Provided is an intraocular lens injector that allows a haptic and a optic to be pushed in reliably. The intraocular lens injector includes a lens holder holding an intraocular lens which has a optic and a haptic extending in a curved shape from the optic, a device body to which the lens holder is attached, a plunger inserted projectably/retractably in the device body and coming into contact with the intraocular lens to push out this intraocular lens, and a nozzle portion connected to the device body, the nozzle portion releasing the intraocular lens while folding the intraocular lens concavely by a push-in operation of the plunger. A positioner is provided to push up the haptic along a thickness direction of the optic within a range contactable with a distal end of the plunger, when the lens holder and the intraocular lens are attached to the device body.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: June 5, 2018
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Christian Winfried Wagner, Yoshitaka Yamada, Katsuyuki Ueno
  • THERAPEUTIC AGENT FOR DRY EYE CHARACTERIZED BY BEING APPLIED TO EYE OF DRY EYE PATIENT WEARING SOFT CONTACT LENS
    Publication number: 20180147230
    Abstract: An ophthalmic solution, which comprises diquafosol tetrasodium salt and is free from benzalkonium chloride, treats onset and/or exacerbation of dry eye symptom caused by wearing soft contact lenses.
    Type: Application
    Filed: June 3, 2016
    Publication date: May 31, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Yoshihiro OSHITA, Hitoshi NAKAZAWA, Isao MATSUOKA, Asuka KAMIMURA
  • DEPOT FORMULATIONS
    Publication number: 20180117016
    Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.
    Type: Application
    Filed: December 28, 2017
    Publication date: May 3, 2018
    Applicants: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Wilma TAMRAZ, Huey-Ching SU, WeiQi LIN, Kazuhito YAMADA, Naoki MATSUMOTO, Sreenivasu MUDUMBA, Komei OKABE
  • Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
    Patent number: 9943510
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: April 17, 2018
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
  • DRY EYE THERAPEUTIC AGENT COMPRISING NANDROLONE OR ESTER THEREOF OR METHENOLONE OR ESTER THEREOF AS AN ACTIVE INGREDIENT
    Publication number: 20180071313
    Abstract: An object of the present invention is to provide a novel dry eye therapeutic agent that demonstrates superior dry eye therapeutic effects, and from the viewpoint of the drug administration burden of the patient, is capable of demonstrating a medicinal effect over a long period of time in lacrimal gland tissue after the administration thereof. A dry eye therapeutic agent comprising nandrolone or an ester thereof or methenolone or an ester thereof is therapeutically effective on dry eye since it increases the amount of tear lipocalin (TL) in tears, and medicinal effects can be demonstrated over a long period of time in lacrimal gland tissue by administering a dry eye therapeutic agent comprising nandrolone or an ester thereof or methenolone or an ester thereof to eyelid skin.
    Type: Application
    Filed: April 1, 2016
    Publication date: March 15, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenichi ENDO, Shinobu FUJII, Kenji OKI
  • PHARMACEUTICAL COMPOSITION COMPRISING POLYPEPTIDE
    Publication number: 20180064818
    Abstract: Found out is a pharmaceutical composition that sustained-releases a drug for a long term after administration into the body. Provided is a pharmaceutical composition comprising a drug and a polypeptide represented by Ac-(Arg-Ala-Asp-Ala)4-NH2, and further containing an organic solvent selected from the group consisting of polyethylene glycol, dimethyl sulfoxide, glycofurol, and N-methylpyrrolidone.
    Type: Application
    Filed: March 16, 2016
    Publication date: March 8, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Tatsuya MIYAZAKI, Kenji MASAKI, Komei OKABE, Kazuhito YAMADA
  • 2-[[[2-[(Hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof
    Patent number: 9902698
    Abstract: In the course of developing 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide(compound A), there are the multiple problems: 1) compound A or its salt is difficult to be recrystallized, the storage stability largely differs depending on the kind of the salt, and it is very difficult to obtain a salt of compound A having excellent storage stability; 2) in a crystallization process of compound A, it is very difficult to control a crystal polymorph, and 3) compound A (free body) causes mineral deposition in the stomach when it is orally administered repeatedly.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: February 27, 2018
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masashi Niwa, Hiroshi Deguchi
  • SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION
    Publication number: 20180042907
    Abstract: The present invention relates to an ophthalmic depot preparation comprising benzyl benzoate and/or benzyl alcohol and polyethylene glycol and/or dimethylsulfoxide, wherein the volume ratio of benzyl benzoate and/or benzyl alcohol to polyethylene glycol and/or dimethylsulfoxide in the ophthalmic depot preparation is 75:25 to 25:75, and the total amount of benzyl benzoate and/or benzyl alcohol and polyethylene glycol and/or dimethylsulfoxide contained is 50% (w/w) or more.
    Type: Application
    Filed: March 17, 2016
    Publication date: February 15, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD
    Inventors: Komei OKABE, Toyomi FUJISAWA, Kazuhito YAMADA
  • THERAPEUTIC AGENT FOR MEIBOMIAN DYSFUNCTION
    Publication number: 20180021314
    Abstract: A method for treatment of meibomian gland dysfunction in a mammalian subject, the method involving administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to the eyes of the mammalian subject 1 to 2 times per day.
    Type: Application
    Filed: October 2, 2017
    Publication date: January 25, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki MIYAKE, Tomoko ODA, Daisuke SHII